Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) have been assigned an average recommendation of “Buy” from the seventeen analysts that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $142.43.

Several research firms have commented on CRL. Barclays increased their price target on shares of Charles River Laboratories Intl. from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, March 18th. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “sell” rating to a “hold” rating and set a $156.00 price target for the company in a research report on Thursday, February 14th. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Deutsche Bank initiated coverage on shares of Charles River Laboratories Intl. in a research report on Friday, December 14th. They issued a “buy” rating for the company. Finally, KeyCorp increased their price objective on shares of Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research report on Monday, March 11th.

In other Charles River Laboratories Intl. news, Director Stephen D. Chubb sold 4,540 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $141.23, for a total transaction of $641,184.20. Following the completion of the transaction, the director now directly owns 38,868 shares of the company’s stock, valued at approximately $5,489,327.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Foster sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $146.02, for a total transaction of $438,060.00. Following the transaction, the chief executive officer now directly owns 286,397 shares of the company’s stock, valued at $41,819,689.94. The disclosure for this sale can be found here. Insiders sold a total of 57,428 shares of company stock valued at $7,472,693 over the last ninety days. 2.10% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Fort L.P. purchased a new position in Charles River Laboratories Intl. during the 4th quarter worth approximately $27,000. Riverview Trust Co purchased a new position in Charles River Laboratories Intl. during the 4th quarter worth approximately $30,000. Kwmg LLC raised its position in Charles River Laboratories Intl. by 32.4% during the 4th quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after buying an additional 105 shares during the last quarter. Captrust Financial Advisors raised its position in Charles River Laboratories Intl. by 101.3% during the 4th quarter. Captrust Financial Advisors now owns 612 shares of the medical research company’s stock worth $69,000 after buying an additional 308 shares during the last quarter. Finally, Csenge Advisory Group purchased a new position in Charles River Laboratories Intl. during the 3rd quarter worth approximately $91,000. 94.83% of the stock is owned by institutional investors.

Shares of CRL stock traded up $2.10 during mid-day trading on Thursday, hitting $143.34. 250,117 shares of the stock traded hands, compared to its average volume of 381,611. The firm has a market cap of $6.81 billion, a price-to-earnings ratio of 23.77, a PEG ratio of 1.84 and a beta of 1.04. Charles River Laboratories Intl. has a 52-week low of $101.58 and a 52-week high of $147.72. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.38 and a current ratio of 1.61.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 13th. The medical research company reported $1.49 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.10. The business had revenue of $605.53 million during the quarter, compared to analyst estimates of $589.86 million. Charles River Laboratories Intl. had a net margin of 9.99% and a return on equity of 24.09%. The company’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.40 earnings per share. As a group, equities analysts predict that Charles River Laboratories Intl. will post 6.48 earnings per share for the current fiscal year.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: NASDAQ

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.